Your session is about to expire
← Back to Search
ARV-766 +/- Abiraterone for Prostate Cancer
Study Summary
This trial will test a new drug, ARV-766, to see if it is safe and effective in treating men with prostate cancer that has spread and is resistant to hormone therapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
Are people still able to join this research project?
"The online clinical trials database indicates that this study is actively looking for participants. This particular trial was originally posted on September 2nd, 2021 and has seen one update since then on October 28th, 2022."
How many different hospitals are conducting this study?
"There are 15 sites currently running this study, spanning from Charlottesville to Detroit. If you are selected for the trial, it is important to choose a location close to minimize travel time and costs."
How many individuals are being helped by this clinical trial?
"Yes, that is correct. The clinicaltrials.gov website has information indicating that the study is looking for recruitment of 150 patients from 15 different medical sites. The original posting was on September 2nd, 2021 and there was a recent update on October 28th, 2022."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger